Identification of potential P. falciparum transketolase inhibitors: pharmacophore design, in silico screening and docking studies

Shweta Joshi, Alok Ranjan Singh, Uzma Saqib, Prakash Chandra Misra, Mohammad Imran Siddiqi, Jitendra Kumar Saxena

.

DOI: 10.4236/jbpc.2010.12012                

Abstract

Transketolase, the most critical enzyme of the non-oxidative branch of the pentose phosphate pathway, has been reported as a novel target in Plasmodium falciparum as it has least homology with the human host. Homology model of P. falciparum transketolase (PfTk) was constructed using the crystal structure of S. cervisiae transketolase as a template, and used for the identification and prioritization of potential compounds targeted against Plasmodium falciparum transketolase. The docking studies with fructose-6-phosphate and thiamine pyrophosphate showed that His31, Asp473, Ser388, Arg361 and His465 formed hydrogen bonds with fructose-6-phosphate while pyrimidine ring of coenzyme interacted with conserved residues of protein viz., Leu121, Glu415, Gly119. The major interacting residues involved in binding of oxythiamine pyrophosphate were similar to cofactor binding site of PfTk. An integrated pharmacophore, co-factor ThDP and substrate fructose-6-pho- sphate, based virtual screening of a small mo- lecule database retrieved eight and thirteen compounds respectively. When screened for their activity against P. falciparum transketolase, one compound in case of ThDP and three compounds in case of fructose-6-phosphate based screening were found active against PfTk. Identification of these novel and chemically diverse inhibitors provides initial leads for optimization of more potent and efficacious drug candidates to treat malarial infection.

Keywords

Plasmodium Falciparum Transketolase

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Comín-Anduix, B., Boren, J., Martinez, S., Moro, C., Ce- ntelles, J.J., Trebukhina, R., Petushok, N., Lee, W.N., Boros, L.G. and Cascante, M. (2001) The effect of thia- mine supplementation on tumour proliferation. A meta- bolic control analysis study. European Journal of Bio- chemistry, 268(15), 4177-4182.
[2]	Mazzola, J.L. and Sirover, M.A. (2004) Subcellular ana- lysis of aberrant protein structure in age-related neuro- degenerative disorders,” Journal of Neuroscience Methods, 137(2), 241-246.
[3]	Saito, N., Kimura, M., Kuchiba, A. and Itokawa, Y. (1987) The relationship between blood thiamine levels and die- tary thiamine content in diabetic outpatients and healthy subjects. Journal of Nutrition Science Vitaminology, 33(6), 431-438.
[4]	Rais, B., Comin, B., Puigjaner, J., Brandes, J.L., Creppy, E., Saboureau, D., Ennamany, R., Lee, W.N.P., Boros, L.G. and Cascante, M. (1999) Oxythiamine and dihydroe- piandrosterone induce a G1 phase cycle arrest in Eher- lich’s tumor cells through inhibition of the pentose cycle. FEBS Letters, 456(1), 113-118.
[5]	Shreve, D.S., Holloway, M.P., Haggerty, J.C. III and Sable, H.Z. (1993) The catalytic mechanism of trans- ketolase. Thiamin pyrophosphate-derived transition states for Transketolase and pyruvate dehydrogenase are not identical. Journal of Biological Chemistry, 258(20), 12405- 12408.
[6]	Schellenberger, A. (1992) Thiamin pyrophosphate bind- ing mechanism and the function of the aminopyrimidine part. Journal of Nutritional Science and Vitaminology (Tokyo), 392-396.
[7]	Boros, L.G., Puigjaner, J., Cascante, M., Lee, W.N., Brandes, J.L., Bassilian, S., Yusuf, F.I., Williams, R.D., Muscarella, P., Melvin, W.S. and Schirmer, W.J. (1999) Oxythiamine and dehydroepiandrosterone inhibit the non-oxidative synthesis of ribose and tumor cell proli- feration. Cancer Research, 57(19), 4242-4248.
[8]	Nilsson, U., Lindqvist, Y., Kluger, R. and Schneider, G. (1993) Crystal structure of Transketolase in complex with thiamine thiazolone diphosphate, an analogue of the reaction intermediate, at 2.3A? resolution. FEBS Letters, 326(3), 145-148.
[9]	Wikner, C., Nilsson, U., Meshalkina, L., Udekwu, C., Lindqvist, Y. and Schneider, G. (1997) Identification of catalytically important residues in yeast Transketolase. Biochemistry, 36(50), 15643-15649.
[10]	Lindqvist, Y., Schneider, G., Ermler, U. and Sundstrom, M. (1992) Three-dimensional structure of transketolase, a thiamine diphosphate dependent enzyme, at 2.5 ? reso- lution. European Molecular Biology Organization Jour- nal, 11(7), 2373-2379.
[11]	Nikkola, M., Lindqvist, Y. and Schneider, G. (1994) Refined structure of transketolase from Saccharomyces cerevisiae at 2.0A? resolution. Journal of Molecular Biology, 238(3), 387-404.
[12]	Isupov, M.N., Rupprecht, M.P., Wilson, K.S., Dauter, Z. and Littlechild, J.A. Crystal Structure of Escherichia coli Transketolase. In press.
[13]	Gerhardt, S., Echt, S., Busch, M., Freigang, J., Auerbach, G., Bader, G., Martin, W.F., Bacher, A., Huber, R. and Fischer, M. (2003) Structure and properties of an engi- neered transketolase from maize. Plant Physiology, 132(4), 1941-1949.
[14]	Obiol-Pardo, C. and Rubio-Martinez, J. (2009) Homology modelling of human Transketolase: Description of criti- cal sites useful for drug design and study of the cofactor binding mode. Journal of Molecular Graphics and Mo- delling, 27(8), 723-734.
[15]	Joshi, S., Singh, A.R., Kumar, A., Misra, P.C., Siddiqi, M.I. and Saxena, J.K. (2008) Molecular cloning and characterization of Plasmodium falciparum transketolase. Molecular and Biochemical Parasitology, 160(1), 32-41.
[16]	Sali, A. and Blundell, T.L. (1993) Comparative protein modeling by satisfaction of spatial restraints. Journal of Molecular Biology, 234(3), 779-815.
[17]	Accelrys Inc. (2001) Insight II 2000.1 program. Accelrys Inc., San Diego.
[18]	Fiser, A., Do, R.K. and Sali, A. (2000) Modeling of loops in protein structures. Protein Science, 9(9), 1753-1773.
[19]	Laskowski, R.A., MacArthur, M.W., Moss, D.S. and Thor- nton, J.M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography, 26(2), 283-291.
[20]	Nilsson, U., Meshalkina, L., Lindqvist, Y. and Schneider, G. (1997) Examination of substrate binding in thiamine diphosphate dependent transketolase by protein crystallography and site-directed mutagenesis. Journal of Biological Chemistry, 272(3), 1864-1869.
[21]	Asztalos, P., Parthier, C., Golbik, R., Kleinschmidt, M., Hübner, G., Weiss, M.S., Friedemann, R., Wille, G. and Tittmann, K. (2007) Strain and near attack conformers in enzymic thiamin catalysis: X-ray crystallographic snapshots of bacterial transketolase in covalent complex with donor ketoses xylulose 5-phosphate and fructose 6-phos- phate, and in noncovalent complex with acceptor aldose ribose 5-phosphate. Biochemistry, 46(43), 12037-12052.
[22]	Wood, T. and Fletcher, S. (1978) The affinity chromatography of transketolase. Biochemica Biophysica Acta, 527(1), 249-255.
[23]	Kochetov, G.A. (1982) Determination of transketolase activity via ferricyanide reduction. Methods in Enzymology, 89, 43-44.
[24]	Edsall, J.T., Flory, P.J., Kendrew, J.C., Liquori, A.M., Nemethy, G., Ramachandran, G.N. and Scheraga, H.A. (1996) A proposal of standard conventions and nomenclature for the description of polypeptide conformations. Journal of Molecular Biology, 15(4), 399-407.
[25]	Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advances in Drug Delivery Review, 46(1-3), 3-26.
[26]	Kramer, B., Rarey, M. and Lengauer, R. (1999) Evaluation of the FlexX incremental construction algorithm for protein ligand docking. Proteins: Structure, Function and Genetics, 37(2), 228-241.
[27]	Rarey, M., Kramer, B., Lengauer, T. and Klebe, G. (1996) A fast flexible docking method using an incremental construction algorithm. Journal of Molecular Biology, 261(3), 470-489.
[28]	Abagyan, R. and Totrov, R. (2001) High throughput do- cking for lead generation. Current Opinion in Chemical Biology, 5(4), 375-382.
[29]	Bissantz, C., Folkers, G. and Rognan, D. (2000) Protein based virtual screening of chemical databases 1. Evaluation of different docking/scoring combinations. Journal of Medicinal Chemistry, 43(25), 4759-4767.
[30]	Rester, U. (2008) From virtuality to reality-virtual scree- ning in lead discovery and lead optimization: A medi- cinal chemistry perspective. Current Opinion in Drug Discovery & Development, 11(4), 559-568.
[31]	Rollinger, J.M., Stuppner, H. and Langer, T. (2008) Virtual screening for the discovery of bioactive natural products. Progress in Drug Research, 65(211), 213-249.